Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of CP-751,871 monotherapy in recurrent or metastatic squamous head and neck carcinoma
2008-004707-59Phase 2Completed
- Sponsor
- King Albert II Cancer Institute
- Start
- Oct 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of figitumumab in head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC), sponsored by King Albert II Cancer Institute. Primary endpoints: Safety profile of CP-751,871 monotherapy and Overall response rate. Started Oct 2008; status: completed.
02
Drugs
figitumumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-004707-59.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004707-59.